Does Estrogen Make Endometriosis Worse?

Estrogen is one of the central drivers of endometriosis, fueling nearly every step of the disease from the survival of misplaced tissue to the inflammation and pain it causes. Endometriotic lesions do not simply respond to the estrogen circulating in your bloodstream; they produce their own, creating a self-reinforcing cycle that can persist even when systemic hormone levels drop. That relationship between estrogen and endometriosis is more layered than it first appears, though, because the disease also rewires how cells sense and respond to hormones in ways that make it resistant to the body’s usual checks.

How Lesions Generate Their Own Estrogen

In healthy tissue, the uterine lining does not manufacture meaningful amounts of estrogen on its own. Endometriotic lesions are different. They contain high levels of an enzyme called aromatase, which converts other hormones into estradiol, the most potent form of estrogen. Normal endometrium from disease-free women shows little to no aromatase activity, but endometriotic implants produce it in abundance.¹ This means lesions can supply themselves with estrogen regardless of what the ovaries are doing.

Research on ovarian endometriomas found that estrogen concentrations inside those cysts were much higher than in normal endometrium, peritoneal lesions, or deep endometriosis. Aromatase gene expression was particularly elevated during the proliferative phase of the menstrual cycle in ovarian endometriomas and in deep lesions.² The lesion essentially builds its own estrogen supply chain. And because estrogen, in turn, stimulates more aromatase production, the cycle feeds itself.³ Meanwhile, the enzymes that normally break down and inactivate estrogen are underexpressed in endometriotic tissue, so local estrogen levels stay high.

Shifted Estrogen Receptors and Progesterone Resistance

Endometriotic tissue does not just have more estrogen floating around; it also changes the way cells detect that estrogen. There are two main types of estrogen receptor: ERα and ERβ. In the normal uterine lining, ERα dominates. In endometriotic lesions, the balance tips. Ovarian lesions, for instance, showed the lowest expression of ERα and the highest expression of ERβ in a tissue microarray study, creating a large ERβ-to-ERα ratio.⁴ Work on peritoneal and ovarian endometriosis confirmed that endometriotic epithelium expresses higher levels of ERβ than ERα, and that this shift coincides with elevated levels of tissue-degrading enzymes.⁵

This receptor shift matters because ERβ activation in endometriotic cells appears to promote inflammation and suppress the progesterone receptor. When progesterone receptors are lost or silenced, the body’s natural brake on estrogen-driven growth stops working. A growing body of evidence shows that progesterone resistance is a hallmark of endometriosis: the tissue simply does not respond to progesterone the way normal endometrium does, leaving estrogen’s effects largely unopposed.⁶ So it is not only that estrogen is overproduced but also that the counterbalancing hormone cannot do its job.

How Estrogen Fuels Tissue Invasion and New Blood Vessels

For a stray piece of endometrial tissue to survive outside the uterus, it needs to invade surrounding structures and build a blood supply. Estrogen actively helps with both. In lab experiments, treating endometrial stromal cells with estradiol increased levels of MMP9, an enzyme that degrades surrounding tissue, by roughly 3.5-fold and VEGF, a protein that stimulates new blood vessel growth, by about 4.2-fold. When estrogen receptor activity was blocked, those increases disappeared.⁷ A separate study in eutopic endometrial cells from women with endometriosis confirmed the same pattern: estrogen stimulated both VEGF and MMP9 through a receptor pathway that stabilizes a factor involved in the tissue’s response to low oxygen.⁸

In practical terms, this means estrogen does not merely keep endometriotic lesions alive. It actively helps them dig in, build infrastructure, and grow. Reducing estrogen exposure shrinks that invasive capacity.

Estrogen Blunts the Immune Response to Lesions

Your immune system should, in theory, recognize and clear tissue that has landed in the wrong place. In endometriosis, that cleanup fails. Estrogen plays a direct part in that failure. One mechanism involves a molecule called CD200: when endometrial stromal cells were stimulated with estradiol, CD200 expression went up, and as CD200 levels rose, the ability of macrophages to engulf and destroy those cells dropped.⁹ The lesion, with estrogen’s help, puts up a molecular “do not eat me” signal.

Estrogen also shapes the broader immune landscape around a lesion. It activates signaling pathways through ERβ that recruit more macrophages to the lesion site, then pushes those macrophages toward an anti-inflammatory state that supports tissue growth rather than tissue destruction. Estrogen-stimulated macrophages secrete growth factors that help the lesion expand.¹⁰ This creates a local environment that is simultaneously inflamed enough to cause pain but immunologically permissive enough to let lesions thrive.

Estrogen also stimulates the secretion of inflammatory cytokines and growth factors from the lesions themselves, and those inflammatory signals in turn stimulate more estrogen production, closing yet another self-reinforcing loop.³

Estrogen, Nerve Growth, and Pain

Pain is the symptom most people with endometriosis want explained and managed. Estrogen contributes here, too. Endometriotic lesions develop their own nerve fiber supply, a process called neuroangiogenesis, and estrogen modulates the expression of neurotrophins like nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), which drive nerve fiber growth into the lesions.¹¹ More nerve fibers winding into an inflamed lesion means more pain signals traveling back to the central nervous system.

Research in women not using oral contraceptives found a weakly positive link between estradiol levels and pelvic pain, though the androgen picture was actually stronger: lower free androgen levels correlated with worse pelvic and period pain.¹² That finding hints that pain in endometriosis is not a simple estrogen-level story. The local tissue-level effects of estrogen on nerve growth and inflammation may matter more than what shows up in a blood draw.

Treatments That Target the Estrogen Connection

Because estrogen is so central to the disease, most medical treatments for endometriosis work by lowering estrogen exposure in one way or another. GnRH antagonists are a newer class of oral medication that suppress ovarian estrogen production. Elagolix, taken at a higher dose, and relugolix both showed meaningful reductions in menstrual pain, non-cyclic pelvic pain, and pain during sex in clinical trials.¹³ These drugs are often given alongside a small “add-back” dose of estrogen and a progestin to protect bone density and limit menopausal side effects, threading the needle between suppressing the disease and keeping systemic estrogen high enough to avoid hot flashes and bone loss.

Aromatase inhibitors take a different approach by blocking the enzyme responsible for local estrogen production within the lesions themselves. A systematic review of their use found that when combined with other hormonal agents, aromatase inhibitors reduced pain scores and lesion size and improved quality of life. In a randomized trial, adding an aromatase inhibitor to a GnRH analogue significantly improved pain beyond what the GnRH analogue alone could achieve.¹⁴ Another systematic review confirmed that aromatase inhibitors combined with progestogens or oral contraceptives reduced pain severity and improved quality of life across multiple observational studies.¹⁵

After excision surgery, continuing hormonal therapy that suppresses estrogen activity reduces the risk of lesions coming back by an estimated 59 to 70 percent and cuts symptom recurrence by about 30 percent over 12 months compared with surgery alone. That statistic alone speaks to how much of recurrence is hormonally driven.

Hormone Replacement Therapy and Recurrence Risk

If you have had a hysterectomy or entered menopause with a history of endometriosis, the question of hormone replacement therapy becomes pointed. In one study of women who had both ovaries removed, none of those who skipped HRT saw endometriosis come back, while about 3.5 percent of those who took HRT experienced a recurrence, working out to just under 1 percent per year. The risk was higher when surgery had been incomplete or when peritoneal involvement was extensive.¹⁶

The type of HRT matters. A systematic review found that the majority of case reports involving recurrence or malignancy in women with a history of endometriosis involved unopposed estrogen, particularly conjugated equine estrogens given without a progestogen. Current recommendations favor continuous combined preparations that include a progestin, though the evidence base remains thin.¹⁷ Separate guidance echoes this, noting that unopposed estrogen carries a higher risk than combined preparations, and suggesting that continuous combined therapy or tibolone are the safer choices.¹⁸

When Endometriosis Persists Without High Estrogen

The estrogen-dependence framework is powerful but not absolute. Postmenopausal endometriosis is rare, yet it exists and challenges the assumption that the disease resolves once estrogen drops. A systematic review and case series found 36 women with symptomatic endometriosis after menopause despite no elevated circulating estrogen and no exogenous estrogen intake. In the majority of these cases, symptoms began more than a decade after menopause.¹⁹ The authors suggested that some genetic or epigenetic event may have enabled estrogen-independent progression, increased the tissue’s sensitivity to the small amounts of estrogen still present, or ramped up local estrogen production within the lesion itself.

Other research confirmed that postmenopausal endometriosis includes persistent or recurrent pelvic pain, pain during sex, bowel or urinary symptoms, and occasional abnormal bleeding, all in a hormonal environment where estrogen should no longer be a major player.²⁰ These cases are uncommon, but they are a reminder that estrogen is the main driver, not the only one. Immune dysfunction, epigenetic reprogramming, and local microenvironment factors also keep lesions going in some people.

Epigenetic Changes That Lock in Estrogen Sensitivity

Part of the reason endometriosis is so persistent may be that the disease changes how genes are read. Abnormal DNA methylation patterns have been found in endometriotic tissue, affecting genes involved in hormone response, immune function, and inflammation. These epigenetic alterations may represent a bridge between the hormonal and environmental factors known to influence endometriosis and the gene expression changes that keep lesions active.²¹ In other words, exposure to estrogen (or to chemicals that act like estrogen) could change the epigenetic settings of the tissue, locking in a pattern of heightened estrogen sensitivity and reduced progesterone response that outlasts the original hormonal signal.

Environmental Chemicals That Mimic Estrogen

Endocrine-disrupting chemicals, substances in the environment that interfere with hormone signaling, have been studied for their potential role in endometriosis. A review of the evidence found that PCBs, dioxins, BPA, and phthalates activate multiple pathways tied to inflammation, estrogen and progesterone signaling, cell survival, and tissue invasion, and concluded that these chemicals individually or collectively contribute to the disease.²² Animal studies have identified multiple chemicals capable of influencing the processes endometriotic tissue needs to survive, though human epidemiological results remain mixed.²³

Phytoestrogens, plant-based compounds found in soy, flaxseed, and red wine (resveratrol), add another layer of complexity. Because they weakly bind estrogen receptors, you might expect them to worsen the disease. But the picture is more nuanced. Some epidemiological studies found an inverse association between soy isoflavone intake and endometriosis risk, and higher urinary levels of certain isoflavones correlated with lower disease severity.²⁴ Lab and animal studies have shown favorable effects for resveratrol, isoflavones, and puerarin, though only resveratrol has shown promising results in human trials so far.²⁵ The leading theory is that weak plant estrogens may compete with the body’s stronger estradiol for receptor binding, effectively diluting the hormonal signal that drives the disease. But the research is early enough that no dietary recommendation can be made with confidence.

Estrogen and the Risk of Malignant Transformation

Endometriosis-associated ovarian cancer is rare, but the overlap between the two conditions is an active area of research. Disruptions in estrogen and progesterone receptor expression have been linked to malignant progression in endometriotic tissue. Exposure to estrogens, such as through postmenopausal HRT, raises the likelihood of certain ovarian cancer subtypes, particularly endometrioid carcinoma. Epidemiological studies show that oral contraceptives, which suppress ovulation and alter the hormonal environment, reduce the risk of ovarian cancer.²⁶ This adds yet another reason to take estrogen’s role in endometriosis seriously, especially in decisions about long-term hormone therapy after menopause.

Why Only Humans and Other Primates Get It

One often-overlooked fact: spontaneous endometriosis occurs only in humans and nonhuman primates.²⁷ Other mammals can be induced to develop it in the lab, but they do not develop it on their own. The shared trait between humans and their primate relatives is menstruation with retrograde flow, the backward movement of menstrual tissue through the fallopian tubes into the pelvis. That process sets the stage, but it is the hormonal environment, dominated by estrogen, that determines whether those displaced cells survive and grow into disease. Understanding this evolutionary context reinforces why the hormonal angle is central and why treatments that modify the estrogen environment remain the backbone of medical management.